Why the study?
COVID-19 affects the cardiovascular system leading to vasculopathies that exhibit differences in epidemiology, clinical characteristics, and outcome compared to non-COVID-19 types.
This review highlights the distinct epidemiological and clinical features of COVID-19 associated vasculopathies compared to non-COVID-19 cohorts.
May prompt tailored evaluation of COVID-19 vasculopathies; leaves open prospective studies to guide management.
Coronavirus disease 19 (COVID-19) has shown to be an infectious disease affecting not only of the respiratory system, but also cardiovascular system leading to different COVID-19-associated vasculopathies. Venous and arterial thromboembolic events have been frequently described among hospitalized patients with COVID-19 and inflammatory vasculopathic changes have also been observed. Several of the reported COVID-19 associated vasculopathies exhibit differences on epidemiology, clinical characteristics and outcome compared to non-COVID-19 types. This review focuses on the epidemiology, clinical, diagnostic and therapeutic characteristics as well as outcome data of COVID-19 associated thromboembolic events and inflammatory vasculopathies, elaborating similarities and differences with non-COVID-19 cohorts.
No takes yet. Share an insight, caveat, or question.
Greistorfer et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: